Brief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
01/06/2026 13:03
BRIEF-Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy June 1 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:
VERTEX ANNOUNCES US FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR ACCELERATED APPROVAL OF POVETACICEPT IN IGA NEPHROPATHY
VERTEX PHARMACEUTICALS - FDA SETS PDUFA DATE FOR POVETACICEPT ON NOVEMBER 30, 2026
Source text: ID:nBw4yDmtba
Further company coverage: VRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria